ReviewCurrent rheumatology reports2016
SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- Orofacial manifestations of SAPHO syndrome: a systematic review of case reports.Clinical rheumatology · 2020Pooled it
- Tripterygium wilfordii Hook F. in the treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a clinical trial.Clinical rheumatology · 2021Trial
- CT and MRI features of SAPHO syndrome: a report of 6 cases.BMC musculoskeletal disorders · 2026Article
- [Inflammatory dermatosis in adult chronic non-bacterial osteomyelitis (adult CNO) from a dermatological perspective].Zeitschrift fur Rheumatologie · 2026Article
- Thymic CT attenuation score in SAPHO syndrome: a comparative study with rheumatoid arthritis, ankylosing spondylitis, and healthy controls.Frontiers in immunology · 2026Article
- Case Report: Successful treatment of SAPHO syndrome refractory to adalimumab with upadacitinib.Frontiers in immunology · 2026Article
- Case Report: Successful management of refractory SAPHO syndrome with guselkumab-upadacitinib combination.Frontiers in immunology · 2026Article
- Bone scintigraphy and SPECT/CT imaging characteristics in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.Quantitative imaging in medicine and surgery · 2025Article
- The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2025Review
- Case Report: Successful treatment of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and palmoplantar pustulosis with ustekinumab.Frontiers in immunology · 2025Article
- SAPHO syndrome: current clinical, diagnostic and treatment approaches.Rheumatology international · 2024Review
- Article
- Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report.Journal of medical case reports · 2024Article
- The role of cytokines in the pathogenesis of SAPHO syndrome.Frontiers in immunology · 2024Review
- Enteropathic SAPHO Syndrome in Ulcerative Colitis Responsive to Bisphosphonates.Case reports in rheumatology · 2024Article
- Article
- Article
- Relapse of Low Back Pain After Internal Lumbar Fixation Was Diagnosed with SAPHO Syndrome: A Case Report.International medical case reports journal · 2023Article
- Article
- Massive calcification around large joints in a patient subsequently diagnosed with adult-onset hypophosphatasia.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare autoimmune disease which, due to its clinical presentation and symptoms, is often misdiagnosed and unrecognized. Its main features are prominent inflammatory cutaneous and articular manifestations. Treatments with immunosuppressive drugs have been used for the management of SAPHO with variable results. To date, the use of anti-TNF-α agents has proved to be an effective alternative to conventional treatment for unresponsive or refractory SAPHO cases. TNF-α is a pro-inflammatory cytokine and pivotal regulator of other cytokines, including IL-1 β, IL-6, and IL-8, involved in inflammation, acute-phase response induction, and chemotaxis. IL-1 inhibition strategies with anakinra have shown efficacy as first and second lines of treatment. In this review, we will describe the main characteristics of biological drugs currently used for SAPHO syndrome. We also describe some of the promising therapeutic effects of ustekinumab, an antibody against the p40 subunit of IL-12 and IL-23, after failure of multiple drugs including anti-TNF-α and anakinra. We discuss the use and impact of the new anti-IL-1 antagonists involved in the IL-17 blockade, in particular for the most difficult-to-treat SAPHO cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.